[Clinical effect of terodiline hydrochloride (TD-758) in patients with urinary disturbances].
We evaluated the efficacy of terodiline hydrochloride (TD-758) in 23 patients with psychosomatic bladder, chronic prostatitis and chronic cystitis. The drug was administered at a dose of 24 mg once a day for 4 weeks. In 78% of the patients the symptoms such as urinary frequency and sense of residual urine improved. Only mild side effects such as thirst were noted. We concluded that terodiline hydrochloride was effective in this trial.
Nakano
M
M
Department of Urology, Hamamatsu, University School of Medicine.
Tajima
A
A
Aso
Y
Y
Suzuki
K
K
Hata
M
M
Tsukada
T
T
Masuda
H
H
Hirose
J
J
Kitagawa
M
M
Nakahara
M
M
D000368:Aged; D002082:Butylamines / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002908:Chronic Disease; D003556:Cystitis / Q000150:complications / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy; D001750:Urinary Bladder, Neurogenic / Q000150:complications / Q000188:drug therapy; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D002082:Butylamines; D002121:Calcium Channel Blockers; C010637:terodiline